Analysts agree tariffs alone won’t bring full pharmaceutical manufacturing back to the U.S. Without government financing and systemic reform, drug prices could soar, supply chains remain fragile, and patients may face higher risks.
(Disclaimer: This slideshow has been sourced from AP)